Table 4. Baseline imbalance of specific non-vaccine types (HPV types 33, 39, 51, and 58) and time of onset of CIN 2/3 cases occurring in the vaccine group.
| Day 1 | Month 1 | Month 2 | Month 3 | Month 4 | |
|---|---|---|---|---|---|
| Case 1 | HSIL; 33;52;58 | 33(CIN 3) | |||
| Case 2 | LSIL; 33;58;59 | 33(CIN 2);58(CIN 2); 59(CIN 2);59(CIN 1); 33(CIN 3);58(CIN 3);59(CIN 3) | |||
| Case 3 | HSIL; 16;35;58 | 51(CIN 3);58(CIN 3) | |||
| Case 4 | 51 | 51(CIN 2) | |||
| Case 5 | HSIL; 16;58 | 16(CIN 1);58(CIN 1) 16(CIN 3);58(CIN 3); 16(CIN);58(CIN 1) | |||
| Case 6 | ASCUS HR-HPV+ 31;58 | 31(CIN 2);58(CIN 2) | |||
| Case 7 | LSIL; 51 | 51(CIN 2) | |||
| Case 8 | HSIL; 16;39;52 | — | 39(CIN 3);16(CIN 1);39(CIN 1); 52(CIN 1) | ||
| Case 9 | ASCUS HR-HPV+ 51 | 51(CIN 2) | |||
| Case 10 | 33 | 33(CIN 2) | |||
| Case 11 | LSIL; 45;51;52 | 52(CIN 3); 52(CIN 2) | 45(CIN 3);51(CIN 3); 52(CIN 3); 52(CIN 2) |
Abbreviations: ASCUS=Atypical squamous cells of undetermined significance; CIN=cervical intraepithelial neoplasia; HSIL=high-grade squamous intraepithelial lesion; HPV=human papillomavirus; HR=high-risk probe result; LSIL=low-grade squamous intraepithelial lesion.